Baseline lymphopenia as prognostic factor in patients with metastatic breast cancer treated with palbociclib

  • Authors:
    • George Emile
    • Sarah Penager
    • Christelle Levy
    • Alison Johnson
    • Djelila Allouache
    • Justine Lequesne
    • Ioana Hrab
    • Carine Segura
    • Adeline Morel
    • Katarina Gunzer
    • Audrey Faveyrial
    • Francois Cherifi
    • Angelique Da Silva
  • View Affiliations

  • Published online on: November 19, 2021     https://doi.org/10.3892/ol.2021.13143
  • Article Number: 25
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cyclin‑dependent‑kinase 4‑6 inhibitors (CDK4/6i) have improved the management of hormone receptor (HR)+/human epidermal growth factor receptor (HER)2‑ metastatic breast cancer (mBC). Currently, there are no valid prognostic factors for response to CDK4/6i. Baseline lymphopenia is reported as a prognostic factor in several types of cancer. The present retrospective study aimed to evaluate the effect of baseline absolute lymphocyte count (ALC) on response to palbociclib. Progression‑free survival (PFS) was the primary endpoint. Secondary endpoints were overall survival (OS), best response and safety. A total of 114 patients treated for mBC between 2016 and 2019 were included. Median baseline ALC was 1.4 g/l (range, 0.2‑4.3 g/l). A total of 65 (57%) and 49 (43%) patients had baseline ALC values of <1.5 and ≥1.5 g/l, respectively. Patients with baseline lymphopenia exhibited significantly shorter PFS (6 vs. 10 months; P=0.004) and OS (20 vs. 33 months; P=0.02). ALC <1.5 g/l independently predicted worse survival, as indicated by multivariate analysis (P=0.04; hazard ratio, 1.76; 95% confidence interval, 1.02‑3.02). Patients with baseline ALC <1.5 g/l had significantly less partial response (14 vs. 22%; P=0.016) and more disease progression (46 vs. 20%; P=0.016) than those with ALC ≥1.5 g/l. ALC is a strong and easy‑to‑use dosage with prognostic factor for patients with HR+/HER2 mBC treated with palbociclib and endocrine therapy. Lymphopenia may also be a predictive factor of early progression. These data need to be verified in a larger prospective study.
View Figures
View References

Related Articles

Journal Cover

January-2022
Volume 23 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Emile G, Penager S, Levy C, Johnson A, Allouache D, Lequesne J, Hrab I, Segura C, Morel A, Gunzer K, Gunzer K, et al: Baseline lymphopenia as prognostic factor in patients with metastatic breast cancer treated with palbociclib. Oncol Lett 23: 25, 2022
APA
Emile, G., Penager, S., Levy, C., Johnson, A., Allouache, D., Lequesne, J. ... Da Silva, A. (2022). Baseline lymphopenia as prognostic factor in patients with metastatic breast cancer treated with palbociclib. Oncology Letters, 23, 25. https://doi.org/10.3892/ol.2021.13143
MLA
Emile, G., Penager, S., Levy, C., Johnson, A., Allouache, D., Lequesne, J., Hrab, I., Segura, C., Morel, A., Gunzer, K., Faveyrial, A., Cherifi, F., Da Silva, A."Baseline lymphopenia as prognostic factor in patients with metastatic breast cancer treated with palbociclib". Oncology Letters 23.1 (2022): 25.
Chicago
Emile, G., Penager, S., Levy, C., Johnson, A., Allouache, D., Lequesne, J., Hrab, I., Segura, C., Morel, A., Gunzer, K., Faveyrial, A., Cherifi, F., Da Silva, A."Baseline lymphopenia as prognostic factor in patients with metastatic breast cancer treated with palbociclib". Oncology Letters 23, no. 1 (2022): 25. https://doi.org/10.3892/ol.2021.13143